Related Experiment Video

Updated: Aug 20, 2026

Isolating Primary Melanocyte-like Cells from the Mouse Heart
07:38

Isolating Primary Melanocyte-like Cells from the Mouse Heart

Published on: September 29, 2014

MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A

Amy E Loercher1, Elizabeth M H Tank, Rachel B Delston

  • 1Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA.

The Journal of Cell Biology
|December 30, 2004
PubMed

Insights

The microphthalmia transcription factor (MITF) drives cell cycle exit by activating the INK4A inhibitor, crucial for melanocyte differentiation and tumor suppression. This link explains INK4A mutations in melanoma.

Area of Science:

  • Cell Biology
  • Developmental Biology
  • Cancer Biology

Background:

  • Cell cycle exit is essential for cell differentiation, development, and tumor suppression.
  • The precise molecular mechanisms connecting cell cycle exit and differentiation are not fully understood.
  • Melanocyte differentiation relies on the microphthalmia transcription factor (MITF).

Purpose of the Study:

  • To elucidate the mechanisms linking cell cycle exit with differentiation.
  • To investigate the role of MITF in regulating cell cycle exit.
  • To explore the relationship between MITF, INK4A, and melanocyte differentiation.

Main Methods:

  • Analysis of MITF binding to the INK4A promoter.
  • Measurement of p16(Ink4a) mRNA and protein expression.
  • Assessment of retinoblastoma protein phosphorylation status.
  • Evaluation of MITF's requirement for melanocyte differentiation and INK4A maintenance.

Main Results:

  • MITF directly activates the INK4A promoter, increasing p16(Ink4a) expression.
  • MITF induces cell cycle arrest by causing hypophosphorylation of the retinoblastoma protein.
  • Activation of INK4A by MITF is necessary for effective melanocyte differentiation.
  • MITF maintains INK4A expression in differentiated melanocytes, creating pressure for INK4A inactivation.

Conclusions:

  • INK4A is regulated by a key differentiation factor, MITF.
  • A mechanistic link between melanocyte differentiation and cell cycle exit is established.
  • The findings offer a potential explanation for INK4A mutations in melanoma.

More Related Videos

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...